HST101 not checked
Hasten Biopharmaceutical Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Hypercholesterolemia (2 trials), Dyslipidemias, Primary Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia, Hyperlipidemia; Mixed, Metabolic Disease, ASCVD, LDL-Cholesterol
- Main trialPhase 3
- “This randomized study is to assess LDL-C reductions at Week 12 with monthly (Q4W \[≤31 days\]) dosing of HST101 (lerodalcibep) 300 mg administered subcutaneously (SC) compared to placebo in patients with atherosclerotic cardiovascular disease (ASCVD) or very-high/high risk for ASCVD including Heterozygous familial hypercholesterolemia (HeFH) on a stable diet and oral LDL-C lowering drug therapy, followed by 36-week open-label treatment with subsequent 4-week follow-up for total 52-week long-term safety and efficacy evaluation.”In the company’s words, NCT06568471 on ClinicalTrials.gov
- Other names
- Lerodalcibep
Other drugs for Hypercholesterolemia
- ObicetrapibNewAmsterdam Pharma · Phase 3
- Laroprovstat/rosuvastatinAstraZeneca · Phase 3
- LaroprovstatAstraZeneca · Phase 3
- FDC laroprovstat/RosuvastatinAstraZeneca · Phase 3
- EnlicitideMerck & Co. · Phase 3
- Bempedoic acid/ezetimibeDaiichi Sankyo · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Feb 2026 | A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia | |
| Phase 1Enrolling by invitation | 8 Jan 2025 | A Study on Evaluating the Safety of HST101 in Healthy Chinese Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026